#1 - AbbVie (NYSE:ABBV)
Biopharmaceutical company AbbVie Inc. (NYSE: ABBV) is best known for its flagship psoriatic arthritis drug, Humira. As shareholders know, Humira is no longer protected from biosimilar competition in the United States and Europe. And the logical question is how much of a hit, if any, it will be to the company’s earnings and revenue.
So far, the answer is not much. The company continues to grow both its topline and bottom lines year-over-year with drugs like Rinvoq and Skyrizi picking up some of the revenue losses from Humira. And the company has a deep pipeline of 90 candidates, with 50 of those in mid- to late-stage clinical trials.
ABBV stock has delivered an impressive 762.79% total return over the last 20 years. That's an average of 38% per year. The company is also a Dividend King that has increased its dividend payout for 53 consecutive years. Of the 24 analysts tracked by MarketBeat, 19 give the stock a Buy rating, two of those being Strong Buy ratings.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
More about AbbVie- Current Price
- $216.62
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $211.45 (-2.4% Downside)
